News
- Author:
- Neil Osterweil
Publish date: July 27, 2020
An expert panel of the American College of Cardiology offers evidence-based guidance for evaluating cardiac complications of COVID-19 infections.
News
- Author:
- Neil Osterweil
Publish date: July 15, 2020
Preinflammatory mesenchymal cells resembling synovial fibroblasts may be markers for flare or potential therapeutic targets.
News
- Author:
- Neil Osterweil
Publish date: July 15, 2020
A commercial bus, modified to carry a mobile CT screening unit, has been reaching high-risk individuals in rural areas who may have otherwise been ...
News
- Author:
- Neil Osterweil
Publish date: July 9, 2020
New proposals to start screening at age 50 rather than 55, and after 20 rather than 30 pack-years of smoking, could benefit Black and female patien...
News
- Author:
- Neil Osterweil
Publish date: July 8, 2020
The investigational DPP1 inhibitor is a nonantibiotic anti-inflammatory agent designed to reduce neutrophil serin...
News
- Author:
- Neil Osterweil
Publish date: July 6, 2020
Clinical worsening was reduced for patients with interstitial lung disease–associated pulmonary hypertension, compared with placebo.
News
- Author:
- Neil Osterweil
Publish date: July 2, 2020
The investigational fusion protein sotatercept is thought to reduce pulmonary vascular resistance by reversing remodeling.
News
- Author:
- Neil Osterweil
Publish date: July 1, 2020
A triple inhaler combination with 320 mcg of budesonide was associated with a significantly lower risk of all-cause mortality than a dual-drug inha...
News
- Author:
- Neil Osterweil
Publish date: June 29, 2020
The novel combination showed early efficacy against Philadelphia chromosome–positive leukemias with poor prognose...
News
- Author:
- Neil Osterweil
Publish date: June 24, 2020
Therapy-related ALL appears to be associated with poor prognosis features, but patients who undergo bone marrow t...
News
- Author:
- Neil Osterweil
Publish date: June 24, 2020
Adding the CD38-targeted isatuximab to carfilozimb/dexamethasone also increased the rate of minimal residual dise...
News
- Author:
- Neil Osterweil
Publish date: June 23, 2020
Minimal residual disease was undetectable in peripheral blood of 75% of patients after an ibrutinib lead-in and 12 cycles of the combination.
News
- Author:
- Neil Osterweil
Publish date: June 18, 2020
Patients over 75 and those with secondary AML had longer survival with the addition of venetoclax to azacitidine ...
News
- Author:
- Neil Osterweil
Publish date: June 15, 2020
The combination of obinutuzumab, ibrutinib, and venetoclax was associated with a high complete response rate in t...
News
- Author:
- Neil Osterweil
Publish date: June 5, 2020
The KEYNOTE-604 trial showed a small progression-free survival benefit with the addition of pembrolizumab to standard chemotherapy.
